Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
0 hedge funds and large institutions have $0 invested in Portola Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 162 closing their positions.
100% less funds holding
Funds holding: 162 → 0 (-162)
100% less funds holding in top 10
Funds holding in top 10: 12 → 0 (-12)
100% less capital invested
Capital invested by funds: $1.34B → $0 (-$1.34B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 162
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$126M |
| 2 |
BlackRock
New York
|
-$115M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$72.3M |
| 4 |
Goldman Sachs
New York
|
-$64.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$63.3M |
PTLA Hedge Fund Activity: Q3 2020 in Review
0 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2020, worth a combined $0 — down 100% from $1.34B a quarter earlier.
Sellers outnumbered buyers: 162 funds closed out of PTLA and 0 opened new positions — a net loss of 162 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $126M sold.
- 0 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2020, down from 162 in Q2 2020.
- Funds reported $0 of Portola Pharmaceuticals, Inc. stock for Q3 2020, down 100% quarter-over-quarter.
- 0 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2020 and 162 closed out, a net change of -162 holders.
- The largest Portola Pharmaceuticals, Inc. seller in Q3 2020 was Vanguard Group, an estimated $126M sold.
Based on aggregated 13F filings for Q3 2020.